Windtree Therapeutics Inc (WINT) USD0.001
- Add to watchlist
- This stock can be held in a
Business summary
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics intended to address unmet medical needs in important cardiovascular care markets. The Company’s development programs are primarily focused on the treatment of cardiovascular diseases. Its lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients to treat early cardiogenic shock and acute heart failure (AHF). Its Rostafuroxin is an investigational drug product candidate being developed for the treatment of hypertension in patients with a specific genetic profile. Its heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. The Company is also conducting early exploratory research to assess potential product candidates, including oral and intravenous SERCA2a activator heart failure compounds.
Contact details
Important dates
General stock information
- Short code:
- WINT
- ISIN:
- US97382D4025
- Market cap:
- $3.38 million
- Shares in issue:
- 9.18 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.